SV-BR-1-GM

BIOLOGICAL3 trials

Conditions

Breast CancerBreast Cancer MetastaticBreast NeoplasmBreastcancerEnd Stage CancerMetastatic Breast Cancer

Phase 1

SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer

CompletedNCT03066947

BriaCell Therapeutics CorporationBreastcancer, Breast Neoplasm

Start: 2017-05-05End: 2018-11-22Updated: 2021-01-29

Combination Study of SV-BR-1-GM With Retifanlimab

CompletedNCT03328026

BriaCell Therapeutics CorporationBreast Cancer, Breast Cancer Metastatic, Breast Neoplasm +1

Start: 2018-03-16End: 2026-03-24Updated: 2026-03-27

Phase 3

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

RecruitingNCT06072612

BriaCell Therapeutics CorporationBreast Cancer, Breast Cancer Metastatic, Breast Neoplasm +2

Start: 2023-12-05End: 2028-06-01Target: 404Updated: 2026-04-07

Journal of Clinical Oncology2026-05-27

Quality of life and treatment tolerability of Bria-IMT + CPI in metastatic breast cancer.

Journal of Clinical Oncology2026-05-27

Survival with Bria-IMT + CPI in advanced metastatic breast cancer at 12 and 24 months.

Journal of Clinical Oncology2026-05-27

Abstract CT137: QOL outcomes in Bria-ABC late stage metastatic phase 3 trial

Cancer Research2026-04-17

Abstract PS1-13-23: Survival Results of Phase II Bria-IMT Allogenic Whole Cell-Based Cancer Vaccine

Clinical Cancer Research2026-02-17

Abstract PS1-13-22: Impact of Prior Therapy, Genotype Matching, and Biomarkers in the Bria-ABC Phase 3 Trial

Clinical Cancer Research2026-02-17

Abstract P5-10-12: Bria-IMT CD8+ Tumor Infiltrating Lymphocytes Turn “Cold” Tumor “Hot” in Metastatic Breast Cancer

Clinical Cancer Research2025-06-13

Abstract P2-10-24: ASTRO-VAC CNS : Bria-IMT in the Management of Tumor Agnostic Metastatic CNS Lesions

Clinical Cancer Research2025-06-13

Abstract PS3-04: Overall Survival Results of Bria-IMT Allogenic Whole Cell-Based Cancer Vaccine

Clinical Cancer Research2025-06-13

Abstract P1-01-17: PD-L1 Upregulation in Circulating Tumor Associated Cells Predicts for clinical outcomes in a phase I/II clinical trial using SV-BR-1-GM vaccine with the check point inhibitor retifanlimab in Metastatic Breast Cancer Patients, an Interim Analysis

Clinical Cancer Research2025-06-13

Bria-IMT + checkpoint inhibitor: Phase I/II survival results compared to benchmark trials in metastatic breast cancer.

Journal of Clinical Oncology2025-05-28

Impact of HLA matching on clinical outcomes in a phase 2 trial of Bria-IMT plus anti PD1 in advanced breast cancer.

Journal of Clinical Oncology2025-05-28

Update on phase III pivotal trial of Bria-IMT + CPI vs physician’s choice in advanced metastatic breast cancer (BRIA-ABC).

Journal of Clinical Oncology2025-05-28

Abstract LB408: <i>Bria-</i>ABC vs physician choice in late stage MBC: Early biomarker correlates of the randomized registration trial

Cancer Research2025-04-25

Abstract CT100: Survival outcomes in a randomized phase 2 of<i>Bria-IMT</i>: An allogeneic whole cell cancer vaccine

Cancer Research2025-04-25

Study of the Bria-IMT regimen and CPI vs physicians' choice in advanced metastatic breast cancer (BRIA-ABC).

Journal of Clinical Oncology2024-06-011 citations

Outcomes of advanced/metastatic breast cancer (aMBC) treated with BRIA-IMT, an allogeneic whole cell immunotherapy.

Journal of Clinical Oncology2024-06-011 citations

SV-BR-1-GM after progression on ADC in patients with metastatic breast cancer.

Journal of Clinical Oncology2024-06-01

Differential efficacy of SV-BR-1-GM in inducing intracranial metastasis regression.

Journal of Clinical Oncology2024-06-01

Abstract PO2-13-06: Analysis of Antibody Response to SV-BR-1-GM Therapeutic Vaccine in Breast Cancer Patients Using Human Protein Microarrays: Potential Correlations with Therapy Response

Cancer Research2024-05-021 citations

19 more papers not shown

SV-BR-1-GM

Sponsors

Conditions

Phase 1

Phase 3

Related Papers